Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

EMA seeks views on its access to data policy

By News team

A three-month consultation about releasing clinical trials data which is considered non-commercially sensitive has been launched by the European Medicines Agency.

The draft EMA policy on proactive access to the data will be open for consultation until the end of September 2013. The findings will help shape the EMA’s final strategy, which is due to be published in November.

See also: EMA takes steps towards proactive access to trial data

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2013.11122761

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.